LXRX: Lexicon Pharmaceuticals, Inc. Stock

by  •  • Comments Off on LXRX: Lexicon Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 260.58
Enterprise Value ($M) 166.44
Book Value ($M) 123.03
Book Value / Share 0.34
Price / Book 2.12
NCAV ($M) 67.65
NCAV / Share 0.19
Price / NCAV 3.85

Profitability (mra)
Return on Invested Capital (ROIC) -0.77
Return on Assets (ROA) -0.42
Return on Equity (ROE) -0.61

Liquidity (mrq)
Quick Ratio 2.78
Current Ratio 2.78

Balance Sheet (mrq) ($M)
Current Assets 242.29
Assets 297.67
Liabilities 174.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 31.08
Operating Income -197.12
Net Income -200.40
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -178.78
Cash from Investing -15.38
Cash from Financing 238.35

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-12 13G/A Fmr Llc 9.60 -30.73
12-09 13D/A Invus, L.P. 37.70 0.00
11-14 13G/A Biotechnology Value Fund L P 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2025-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PUR
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-05 2,358,907 7,707,187 30.61
2025-06-04 922,098 3,612,391 25.53
2025-06-03 744,848 1,885,028 39.51
2025-06-02 899,866 2,158,555 41.69

(click for more detail)

Similar Companies
KURA – Kura Oncology, Inc. KYTX – Kyverna Therapeutics, Inc.
LVTX – LAVA Therapeutics N.V. LYEL – Lyell Immunopharma, Inc.
MCRB – Seres Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io